The effect of regadenoson on the integrity of the human blood–brain barrier, a pilot study

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Neuro-Oncology

• Publication date

  2017-03-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11060-017-2404-1PMID 28315063PMCID PMC6341476
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A 2 A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier

  2019cited by this paper
• Systemic therapy for brain metastases.

  2018cited by this paper
• Visual identification of coronary calcifications on attenuation correction CT improves diagnostic accuracy of SPECT/CT myocardial perfusion imaging

  2017cited by this paper
• A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier.

  2016cited by this paper
• The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system?

  2016cited by this paper
• Single photon emission computed tomography imaging of cerebral blood flow, blood–brain barrier disruption, and apoptosis time course after focal cerebral ischemia in rats

  2016cited by this paper
• [Preliminary study on assessment of lexiscan-induced blood-brain barrier opening and its level by CT perfusion imaging].

  2016cited by this paper
• The effect of regadenoson-induced transient disruption of the blood–brain barrier on temozolomide delivery to normal rat brain

  2016cited by this paper
• Relation between stroke severity, patient characteristics and CT-perfusion derived blood-brain barrier permeability measurements in acute ischemic stroke

  2015cited by this paper
• The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

  2015cited by this paper
• Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study

  2015cited by this paper
• Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions

  2015cited by this paper
• Adenosine receptor signaling: a key to opening the blood–brain door

  2015cited by this paper
• Blood-brain barrier imaging in human neuropathologies.

  2014cited by this paper
• Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.

  2014cited by this paper
• A2A Adenosine Receptor Regulates the Human Blood-Brain Barrier Permeability

  2014cited by this paper
• Systemic Therapy of Brain Metastases

  2014cited by this paper
• Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.

  2013cited by this paper
• SPECT-DTPA as a tool for evaluating the blood–brain barrier in post-stroke seizures

  2012cited by this paper
• Evolution of brain imaging instrumentation.

  2011cited by this paper
• Adenosine Receptor Signaling Modulates Permeability of the Blood–Brain Barrier

  2011influential reference
• Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

  2010cited by this paper
• The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation

  2009cited by this paper
• Presurgical 99mTc-sestamibi brain SPET/CT versus SPET: a comparison with MRI and histological data in 33 patients with brain tumours

  2009cited by this paper
• P‐glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism

  2007cited by this paper
• Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group

  2006cited by this paper
• Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas.

  2005cited by this paper
• A Phase I study of concurrent RMP‐7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas

  2005cited by this paper
• Characterization of the Effects of Adenosine Receptor Agonists on Cerebral Blood Flow in Uninjured and Traumatically Injured Rat Brain using Continuous Arterial Spin-Labeled Magnetic Resonance Imaging

  2005cited by this paper
• Phase 1 study of concurrent RMP‐7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas

  2005cited by this paper
• Assessment of myocardial viability.

  2005cited by this paper
• Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients

  2004cited by this paper
• The Effect of RMP-7 and its Derivative on Transporting Evens Blue Liposomes into the Brain

  2004cited by this paper
• A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma.

  2003cited by this paper
• Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport.

  2003cited by this paper
• Tc-99m MIBI Uptake and Its Relation to the Proliferative Potential of Brain Tumors

  2003cited by this paper
• Characterization of a Novel 99mTc-Carbonyl Complex as a Functional Probe of MDR1 P-Glycoprotein Transport Activity

  2002cited by this paper
• Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity.

  2002cited by this paper
• The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain Barrier

  2001cited by this paper
• Evidence that Cereport's ability to increase permeability of rat gliomas is dependent upon extent of tumor growth: implications for treating newly emerging tumor colonies.

  2000cited by this paper
• Enhanced delivery of carboplatin into brain tumours with intravenous CereportTM (RMP-7): dramatic differences and insight gained from dosing parameters

  1999cited by this paper
• Blood-brain barrier and blood volume imaging of cerebral glioma using functional CT: a pictorial review.

  1999cited by this paper
• Blood-brain barrier and blood volume imaging of cerebral glioma using functional CT: a pictorial review.

  1998cited by this paper
• Iodixanol. A review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an x-ray contrast medium.

  1996cited by this paper
• Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.

  1994cited by this paper
• Bradykinin Selectively Opens Blood-Tumor Barrier in Experimental Brain Tumors

  1994cited by this paper
• Radiolabeled agents for SPECT imaging of brain perfusion.

  1990cited by this paper
• Relationship of Octanol/Water Partition Coefficient and Molecular Weight to Cellular Permeability and Partitioning in S49 Lymphoma Cells

  1984cited by this paper
• Heuristic modeling of drug delivery to malignant brain tumors

  1980cited by this paper
• Pictorial review

  1959cited by this paper

• Beyond the Walls of Troy: A Scoping Review on Pharmacological Strategies to Enhance Drug Delivery Across the Blood–Brain Barrier and Blood–Tumor Barrier

  2025cites this paper
• Assessing the dose of regadenoson required to transiently alter blood-brain barrier integrity in patients with infiltrating gliomas

  2025cites this paper
• Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies

  2024cites this paper
• Theobromine improves hyperactivity, inattention, and working memory via modulation of dopaminergic neural function in the frontal cortex of spontaneously hypertensive rats.

  2024cites this paper
• Blood–Brain Barrier Disruption for the Treatment of Primary Brain Tumors: Advances in the Past Half-Decade

  2024cites this paper
• In vivo phenotypic validation of adenosine receptor-dependent activity of non-adenosine drugs

  2023cites this paper
• A high throughput blood-brain barrier model incorporating shear stress with improved predictive power for drug discovery.

  2023cites this paper
• Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions

  2023cites this paper
• Engineered nanomaterials that exploit blood-brain barrier dysfunction fordelivery to the brain.

  2023cites this paper
• ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery

  2023cites this paper
• Recent Trend of Ultrasound-Mediated Nanoparticle Delivery for Brain Imaging and Treatment.

  2022cites this paper
• Towards updated understanding of brain metastasis.

  2022cites this paper
• Smart Nanoformulations for Brain Cancer Theranostics: Challenges and Promises

  2022cites this paper
• Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?

  2022cites this paper
• Multi-disciplinary Approach for Drug and Gene Delivery Systems to the Brain

  2021cites this paper
• Adenosine A2A Receptor Activation Enhances Blood–Tumor Barrier Permeability in a Rodent Glioma Model

  2021cites this paper
• Central nervous system delivery of molecules across the blood-brain barrier.

  2021cites this paper
• Glia-Derived Extracellular Vesicles: Role in Central Nervous System Communication in Health and Disease

  2021cites this paper
• Potential and promising anticancer drugs from adenosine and its analogs.

  2021cites this paper
• Strategies for delivering therapeutics across the blood–brain barrier

  2021cites this paper
• Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus

  2021cites this paper
• Modulation of Blood–Brain Barrier Permeability by Activating Adenosine A2 Receptors in Oncological Treatment

  2021cites this paper
• Breaching the Blood–Brain Tumor Barrier for Tumor Therapy

  2021cites this paper
• Reversible blood-brain barrier opening utilizing the membrane active peptide melittin in vitro and in vivo

  2021cites this paper
• Nerve Growth Factor Biodelivery: A Limiting Step in Moving Toward Extensive Clinical Application?

  2021cites this paper
• Claudin-5: A Pharmacological Target to Modify the Permeability of the Blood-Brain Barrier.

  2021cites this paper
• Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy

  2021cites this paper
• Modulating the Blood–Brain Barrier: A Comprehensive Review

  2021cites this paper
• Modulation of the Blood–Brain Barrier for Drug Delivery to Brain

  2021cites this paper
• Current approaches and prospective drug targeting to brain

  2020cites this paper
• Blood–Brain Barrier Modulation to Improve Glioma Drug Delivery

  2020cites this paper
• Adult precision medicine: learning from the past to enhance the future

  2020cites this paper
• Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome

  2020cites this paper
• Enhanced P-glycoprotein expression under high-altitude hypoxia contributes to increased phenytoin levels and reduced clearance in rats.

  2020cites this paper
• Nanoparticles for Brain Tumor Delivery

  2019cites this paper
• Recent Advances in the Use of Focused Ultrasound for Magnetic Resonance Image-Guided Therapeutic Nanoparticle Delivery to the Central Nervous System

  2019cites this paper
• The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma

  2018cites this paper
• Current Strategies for Brain Drug Delivery

  2018cites this paper
• Targeting WNT Signaling for Multifaceted Glioblastoma Therapy

  2017cites this paper